Harmonizing the preclinical Alzheimer cognitive composite for multicohort studies
- PMID: 35862098
- PMCID: PMC9859944
- DOI: 10.1037/neu0000833
Harmonizing the preclinical Alzheimer cognitive composite for multicohort studies
Abstract
Objectives: Studies are increasingly examining research questions across multiple cohorts using data from the preclinical Alzheimer cognitive composite (PACC). Our objective was to use modern psychometric approaches to develop a harmonized PACC.
Method: We used longitudinal data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), Harvard Aging Brain Study (HABS), and Australian Imaging, Biomarker and Lifestyle Study of Ageing (AIBL) cohorts (n = 2,712). We further demonstrated our method with the Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease (A4) Study prerandomized data (n = 4,492). For the harmonization method, we used confirmatory factor analysis (CFA) on the final visit of the longitudinal cohorts to determine parameters to generate latent PACC (lPACC) scores. Overlapping tests across studies were set as "anchors" that tied cohorts together, while parameters from unique tests were freely estimated. We performed validation analyses to assess the performance of lPACC versus the common standardized PACC (zPACC).
Results: Baseline (BL) scores for the zPACC were centered on zero, by definition. The harmonized lPACC did not define a common mean of zero and demonstrated differences in baseline ability levels across the cohorts. Baseline lPACC slightly outperformed zPACC in the prediction of progression to dementia. Longitudinal change in the lPACC was more constrained and less variable relative to the zPACC. In combined-cohort analyses, longitudinal lPACC slightly outperformed longitudinal zPACC in its association with baseline β-amyloid status.
Conclusions: This study proposes procedures for harmonizing the PACC that make fewer strong assumptions than the zPACC, facilitating robust multicohort analyses. This implementation of item response theory lends itself to adapting across future cohorts with similar composites. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
Figures
Similar articles
-
Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.J Clin Exp Neuropsychol. 2019 Aug;41(6):591-600. doi: 10.1080/13803395.2019.1593949. Epub 2019 Mar 29. J Clin Exp Neuropsychol. 2019. PMID: 30924399
-
Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.J Prev Alzheimers Dis. 2019;6(4):248-255. doi: 10.14283/jpad.2019.25. J Prev Alzheimers Dis. 2019. PMID: 31686097
-
Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.J Alzheimers Dis. 2018;66(3):1193-1211. doi: 10.3233/JAD-180713. J Alzheimers Dis. 2018. PMID: 30412495
-
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4. Cochrane Database Syst Rev. 2014. PMID: 24913723 Free PMC article. Review.
-
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13. Alzheimers Dement. 2019. PMID: 30321505 Review.
Cited by
-
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.Alzheimers Dement. 2024 Jan;20(1):652-694. doi: 10.1002/alz.13449. Epub 2023 Sep 12. Alzheimers Dement. 2024. PMID: 37698424 Review.
-
A guide for researchers seeking training in retrospective data harmonization for population neuroscience studies of Alzheimer's disease and related dementias.Front Neuroimaging. 2022;1:978350. doi: 10.3389/fnimg.2022.978350. Epub 2022 Sep 26. Front Neuroimaging. 2022. PMID: 37464990 Free PMC article.
References
-
- Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR Jr., Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW, & the Alzheimer’s Disease Neuroimaging Initiative. (2010). Clinical core of the Alzheimer’s disease neuroimaging Initiative: Progress and plans. Alzheimer’s and Dementia, 6(3), 239–246. 10.1016/j.jalz.2010.03.006 - DOI - PMC - PubMed
-
- Betthauser TJ, Koscik RL, Jonaitis EM, Allison SL, Cody KA, Erickson CM, Rowley HA, Stone CK, Mueller KD, Clark LR, Carlsson CM, Chin NA, Asthana S, Christian BT, & Johnson SC (2020). Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain: A Journal of Neurology, 143(1), 320–335. 10.1093/brain/awz378 - DOI - PMC - PubMed
-
- Borsboom D (2005). Measuring the mind: Conceptual issues in contemporary psychometrics. Cambridge University Press. 10.1017/CBO9780511490026 - DOI
-
- Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, Doré V, Dobson A, Masters CL, Waller M, Rowe CC, Maruff P, Donohue MC, Rentz DM, Kirn D, … the Alzheimer’s Disease Neuroimaging Initiative, the Australian Imaging, Biomarker and Lifestyle Study of Ageing, the Harvard Aging Brain Study. (2018). Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer’s disease: Findings from three well-characterized cohorts. Alzheimer’s and Dementia, 14(9), 1193–1203. 10.1016/j.jalz.2018.04.010 - DOI - PMC - PubMed
-
- Burnham SC, Bourgeat P, Doré V, Savage G, Brown B, Laws S, Maruff P, Salvado O, Ames D, Martins RN, Masters CL, Rowe CC, Villemagne VL, & the AIBL Research Group. (2016). Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: A longitudinal study. Lancet Neurology, 15(10), 1044–1053. 10.1016/S1474-4422(16)30125-9 - DOI - PubMed
